IOZK Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die unter Beteiligung
von Dr. Wilfried Stücker, Stefaan Van Gool MD. PhD. und Prof. Dr. rer. nat. Volker Schirrmacher veröffentlicht wurden.
Weiterführende Links zum Thema:
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Myeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406Dendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications, IOZK Veröffentlichungen /von 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-14The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73